First-line therapies for patients analyzed in this study: first-line therapies used in the AML cohort
| Characteristic . | 1° AML, no. (%) . | 2° AML, no. (%) . | tAML, no. (%) . |
|---|---|---|---|
| Sample size (N = 114) | 78 (68) | 19 (17) | 17 (15) |
| Intensive therapy (n = 97) | 72 (92) | 10 (53) | 15 (88) |
| Anthracycline + cytarabine only | 31 (40) | 5 (27) | 5 (29) |
| Anthracycline + cytarabine + gemtuzumab | 18 (23) | 0 (0) | 0 (0) |
| Anthracycline + cytarabine + cyclosporin | 13 (17) | 1 (5) | 0 (0) |
| Amonafide + cytarabine | 1 (1) | 1 (5) | 7 (41) |
| Amonafide + gemtuzumab | 1 (1) | 1 (5) | 0 (0) |
| Clofarabine | 6 (8) | 2 (11) | 1 (6) |
| Fludarabine, cytarabine, and filgrastim | 1 (1) | 0 (0) | 2 (12) |
| Gemtuzamab + zosuquidar | 1 (1) | 0 (0) | 0 (0) |
| Intensive intermediate therapy (n = 6) | 3 (4) | 2 (11) | 1 (6) |
| Azacitidine + gemtuzumab | 3 (4) | 2 (11) | 1 (6) |
| Low-dose therapy (n = 7) | 1 (1) | 6 (31) | 0 (0) |
| Decitabine | 0 (0) | 1 (5) | 0 (0) |
| Decitabine + vorinostat | 0 (0) | 2 (11) | 0 (0) |
| Lenalidomide | 0 (0) | 1 (5) | 0 (0) |
| Imatinib | 1 (1) | 0 (0) | 0 (0) |
| Investigational aurora kinase inhibitor | 0 (0) | 1 (5) | 0 (0) |
| Obatoclax mesylate | 0 (0) | 1 (5) | 0 (0) |
| Best supportive care (n = 4) | 2 (3) | 1 (5) | 1 (6) |
| Characteristic . | 1° AML, no. (%) . | 2° AML, no. (%) . | tAML, no. (%) . |
|---|---|---|---|
| Sample size (N = 114) | 78 (68) | 19 (17) | 17 (15) |
| Intensive therapy (n = 97) | 72 (92) | 10 (53) | 15 (88) |
| Anthracycline + cytarabine only | 31 (40) | 5 (27) | 5 (29) |
| Anthracycline + cytarabine + gemtuzumab | 18 (23) | 0 (0) | 0 (0) |
| Anthracycline + cytarabine + cyclosporin | 13 (17) | 1 (5) | 0 (0) |
| Amonafide + cytarabine | 1 (1) | 1 (5) | 7 (41) |
| Amonafide + gemtuzumab | 1 (1) | 1 (5) | 0 (0) |
| Clofarabine | 6 (8) | 2 (11) | 1 (6) |
| Fludarabine, cytarabine, and filgrastim | 1 (1) | 0 (0) | 2 (12) |
| Gemtuzamab + zosuquidar | 1 (1) | 0 (0) | 0 (0) |
| Intensive intermediate therapy (n = 6) | 3 (4) | 2 (11) | 1 (6) |
| Azacitidine + gemtuzumab | 3 (4) | 2 (11) | 1 (6) |
| Low-dose therapy (n = 7) | 1 (1) | 6 (31) | 0 (0) |
| Decitabine | 0 (0) | 1 (5) | 0 (0) |
| Decitabine + vorinostat | 0 (0) | 2 (11) | 0 (0) |
| Lenalidomide | 0 (0) | 1 (5) | 0 (0) |
| Imatinib | 1 (1) | 0 (0) | 0 (0) |
| Investigational aurora kinase inhibitor | 0 (0) | 1 (5) | 0 (0) |
| Obatoclax mesylate | 0 (0) | 1 (5) | 0 (0) |
| Best supportive care (n = 4) | 2 (3) | 1 (5) | 1 (6) |
1° AML indicates de novo AML; 2° AML, AML with antecedent myelodysplasia; and tAML, treatment-related AML.